Skip to main content

Table 3 The tumor volume with anti-PD-1 and/or anti-CD25 associated with anti-TGF-β treatment in different periods

From: CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer

Cohorts Number Day 7 Day 14 Day 21 Day 28 Day 35
Anti-PD-1 5 0.49 ± 0.45 3.02 ± 3.38 10.81 ± 9.82 39.71 ± 27.06 163.50 ± 117.02
Anti-TGF-β+ anti-CD25 5 1.56 ± 1.68 7.61 ± 7.08 34.94 ± 30.67 55.28 ± 41.42 129.87 ± 29.75
Anti-PD-1+ anti-TGF-β+ anti-CD25 5 1.93 ± 1.74 1.46 ± 2.09 1.84 ± 4.04 6.32 ± 14.13 13.31 ± 29.76
Multiple comparision p value 1 vs. 2 0.205 0.227 0.132 0.502 0.906
1 vs. 3 0.139 0.411 0.114 0.050 0.043
2 vs. 3 0.742 0.099 0.044 0.037 0.046
  1. Italic values indicate significance of p value (p<0.05)